कर्नाटका एन्टिबायोटिक्स एण्ड फार्मास्युटिकल्स लिमिटेड
(भारत सरकार का उद्यम)

KARNATAKA ANTIBIOTICS &
PHARMACEUTICALS LIMITED
(A Government of India Enterprise)

ENQUIRY REF No:	KAPL/QAD/020/2149
DATE	20.02.2026
DUE DATE	26.02.2026 (13:00HRS)

Dear Sir,

Please submit your lowest and competitive offer in a SEALED ENVELOPE, DULY SUPERSCRIBING OUR ABOVE ENQUIRY REF. NO., DATE and DUE DATE on it/ OR MAIL, with other details of F.O.R terms, Taxes, Credit period, Delivery offered, Name of the Make, Detailed Specification etc., for below mentioned material/s

SL NO.	ITEM CODE	ITEM DESCRIPTION	UOM	QTY
01	QSPDP3002	25 CM X 4.6 MM 5 MICRON PACKING L1	NOS	01

1) Please ensure that your offer reaches us on or before Due Date by courier OR speed post Or you can also mail us to our email: purenp@kaplindia.com
2) Please send your quotation mentioning item code

OTHER TERMS:

1.	F.O.R TERMS	: DOOR DELIVERY TO PEENYA FACTORY
2.	GST %	: PLEASE SPECIFY
3.	PACKING & FORWARDING CHARGES	: NOT APPLICABLE
4.	CREDIT PERIOD	: 30 DAYS
5.	DELIVERY OFFERED	:
6.	ATTACHED PAGES	: 03

NOTE: IN CASE YOU ARE NOT QUOTING PLEASE SEND THE REGRET LETTER.

Thanking you,

Yours faithfully,
For KARNATAKA ANTIBIOTICS
& PHARMACEUTICALS LIMITED

YUVARAJA M
DEPUTY MANAGER PURCHASE DEPT

User Requirement specifications

Material Description : Stainless steel column 25 cm x 4.6 mm, 5µm Packing L1
URS Number: QC/URS/01/02/26

1. Description and Quantity:

Material Description	25cm x 4.6mm, C8, 5u
Item code	QSDP3002
Quantity/ Box	1

2. User Specifications:

#	Requirement	Specification
1.	Brand Name	25 cm x 4.6 mm, C18, 5µm
2.	Brand	C18
3.	Matrix active group	Silica
4.	Particle size	5u
5.	Length	25 cm
6.	Internal Diameter (I.D.)	4.6 mm
7.	Particle Substrate	Silica
8.	Particle Shape	Spherical
9.	External Construction Materials	Stainless Steel
10.	Endcapped	No
11.	Endfitting Type	Parker-style
12.	USP Classification	L1
13.	Separation Mode	Reverse phase
14.	P^H Range	2-8
15.	Maximum Pressure	6000 psi (415 Bar)
16.	Pore Size	80 °A

.6R,7R)-3-(Acetoxymethyl)-7-[(*Z*)-2-(2-formamidothiazol-4-yl)-2-(methoxyimino)acetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-arboxylic acid.

[e] (6*R*,7*R*)-3-(Acetoxymethyl)-7-[(*E*)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid.

[f] (6*R*,7*R*)-3-[(4-{(*Z*)-2-[(6*R*,7*R*)-3-(Acetoxymethyl)-2-carboxy-5-thia-1-azabicyclo[4.2.0]oct-2-en-7-ylamino]-1-(methoxyimino)-2-oxoethyl}thiazol-2-ylamino)methyl]-7-[(*E*)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid.

[g] (6*R*,7*R*)-3-(Acetoxymethyl)-7-[(*Z*)-2-{2-[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]thiazol-4-yl}-2-(methoxyimino)acetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid.

Organic Impurities, Procedure 2

se *Organic Impurities, Procedure 2*, when the impurity profile includes thiazolylglyoxalic methyloxime, 7-aminocephalosporanic acid, cefotaxime open ring lactone, and bromoacetyl analog.

Buffer: 3.6 g/L of anhydrous dibasic sodium phosphate in water. Adjust with phosphoric acid to a pH of 6.2.

Solution A: Acetonitrile and *Buffer* (2:98)

Solu B: Acetonitrile and *Buffer* (60:40)

Mobile phase: See *Table 3*.

Table 3

Time (min)	Solution A (%)	Solution B (%)
0	100	0
25	80	20
40	60	40
55	0	100
60	0	100
65	100	0
75	100	0

uent: 4.6 g/L of anhydrous dibasic sodium phosphate and 3.5 g/L of monobasic potassium phosphate in water

stem suitability stock solution: 0.1 mg/mL of USP Cefotaxime Related Compound E RS prepared as follows. Dissolve in acetonitrile and *Diluent*, using 20% and 40% respectively of the final volume, sonicate as needed to dissolve, and dilute with *Diluent* to volume.

stem suitability solution: 10 µg/mL of cefotaxime related compound E from *System suitability stock solution* and 1 mg/mL of USP Cefotaxime Sodium RS in *Diluent*. Store refrigerated, and use within 2 h.

ndard solution: 10 µg/mL of USP Cefotaxime Sodium RS in *Diluent*. Store refrigerated, and use within 2 h.

mple solution: 1 mg/mL of Cefotaxime Sodium in *Diluent*. Store refrigerated, and use within 2 h.

omatographic system

e *Chromatography ⟨621⟩, System Suitability*.)

lode: LC

etector: UV 235 nm

olumn: 4.6-mm × 25-cm; 5-µm packing L1

low rate: 1 mL/min

jection volume: 10 µL

utosampler temperature: 4°

tem suitability

amples: *System suitability solution* and *Standard solution*

itability requirements

Resolution: NLT 4.0 between cefotaxime and cefotaxime related compound E, *System suitability solution*

Acceptance criteria: 916–964 µg/mg on the dried basis

IMPURITIES

• Organic Impurities, Procedure 1

Use *Organic Impurities, Procedure 1*, when the impurity profile includes *N*-formyl cefotaxime and cefotaxime dioxime.

Buffer, Solution A, Solution B, Mobile phase, System suitability solution, Sensitivity solution, Standard solution, Sample solution, Chromatographic system, and **System suitability:** Proceed as directed in the *Assay*.

Analysis

Sample: *Sample solution*

Calculate the percentage of each impurity in the portion of Cefotaxime Sodium taken:

$$\text{Result} = [r_U/(r_T + r_C)] \times 100$$

r_U = peak response of each individual impurity

r_T = sum of all of the impurity peak responses

r_C = peak response of cefotaxime

Acceptance criteria: See *Table 2*. The reporting threshold is 0.1%.

Table 2

Name	Relative Retention Time	Acceptance Criteria, NMT (%)
Deacetylcefotaxime[a]	0.26	1.0
Cefetamet[b]	0.52	1.0
Cefotaxime related compound E[c]	0.62	1.0
Cefotaxime	1.0	—
N-Formyl cefotaxime[d]	1.8	1.0
E-Cefotaxime[e]	2.2	1.0
Cefotaxime dimer[f]	2.3	1.0
Cefotaxime dioxime[g]	3.0	0.2
Any individual unspecified impurity	—	0.2
Total impurities	—	3.0

[a] (6*R*,7*R*)-7-[(*Z*)-2-(2-Aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid.

[b] Deacetoxycefotaxime; (6*R*,7*R*)-7-[(*Z*)-2-(2-Aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid.

[c] Deacetylcefotaxime lactone; (*Z*)-2-(2-Aminothiazol-4-yl)-*N*-[(5a*R*,6*R*)-1,7-dioxo-1,3,4,5a,6,7-hexahydroazeto[2,1-*b*]furo[3,4-*d*][1,3]thiazin-6-yl]-2-(methoxyimino)acetamide.